Table 2.
Overview of ongoing clinical trials for new hepatitis B virus therapeutics
| Compound | Phase |
|---|---|
| Entry inhibitors | |
| Myrcludex B | Phase I |
| RNA interference | |
| ALN-HBV | Phase I–II |
| ARC-520 | Phase II |
| ARB-1467 | Phase II |
| Lunar-HBV | Preclinical |
| BB-HB-331 | Preclinical |
| Ionis HBVRx (GSK3228836) | Phase I |
| IONIS-HBVLRx (GSK33389404) | Phase I |
| Capsid assembly modulators/core inhibitors | |
| GLS-4 (morphothiadine mesilate) | Phase II |
| NVR 3-778 | Phase Ia |
| BAY41-4109 | Phase I |
| JNJ56136379 | Phase I |
| Core protein allosteric modifier | Phase I |
| Nucleoside/nucleotide analogues | |
| AGX-1009 (prodrug of tenofovir) | Phase III |
| LB80380 (besifovir) | Phase III |
| CMX-157 (prodrug of tenofovir) | Phase IIa |
| Surface antigen/release inhibitors | |
| REP 2139 and REP 2165 | Phase II |
| RO7020322 (RG7834) | Phase I |
| GC 1102 | Phase II |
| Therapeutic vaccines | |
| GS-4774 (recombinant antigen containing X, Env, core epitopes) | Phase II |
| ABX-203 (recombinant antigen containing HBsAg and HBcAg) | Phase II |
| TG-1050 (nonreplicative adenovirus encoding a large fusion protein (truncated core, modified Pol, and 2 Env domains) | Phase I |
| INO-1800 (DNA plasmids encoding HBsAg and HBcAg) | Phase I |
| FP-02.2 (HepTcell) (peptide encoding CD4+ and CD8+ epitopes) | Phase I |
| Innate immune defense pathway | |
| GS 9620 | Phase II |
| RO6864018 (RG7795, ANA773) | Phase II |
| SB9200 | Phase II |
This table provides a current overview of compounds in clinical development to the best of our knowledge.
HBcAg hepatitis B core antigen, HBsAg hepatitis B surface antigen